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Abstract
Background: There has been little research on design of studies based on routinely collected data when the
clinical endpoint of interest is not recorded, but can be inferred from a prescription. This often happens when
exploring the effect of a drug on chronic diseases. Using the LifeLink claims database in studying the possible anti-
inflammatory effects of statins in rheumatoid arthritis (RA), oral steroids (OS) were treated as surrogate of
inflammatory flare-ups. We compared two cohort study designs, the first using time to event outcomes and the
second using quantitative amount of the surrogate.
Methods: RA patients were extracted from the LifeLink database. In the first study, patients were split into two
sub-cohorts based on whether they were using OS within a specified time window of the RA index date (first
record of RA). Using Cox models we evaluated the association between time-varying exposure to statins and
(i) initiation of OS therapy in the non-users of OS at RA index date and (ii) cessation of OS therapy in the users of
OS at RA index date. In the second study, we matched new statin users to non users on age and sex. Zero inflated
negative binomial models were used to contrast the number of days’ prescriptions of OS in the year following
date of statin initiation for the two exposure groups.
Results: In the unmatched study, the statin exposure hazard ratio (HR) of initiating OS in the 31451 non-users of
OS at RA index date was 0.96(95% CI 0.9,1.1) and the statin exposure HR of cessation of OS therapy in the 6026
users of OS therapy at RA index date was 0.95 (0.87,1.05). In the matched cohort of 6288 RA patients the statin
exposure rate ratio for duration on OS therapy was 0.88(0.76,1.02). There was digit preference for outcomes in
multiples of 7 and 30 days.
Conclusions: The ‘time to event’ study design was preferable because it better exploits information on all available
patients and provides a degree of robustness toward confounding. We found no convincing evidence that statins
reduce inflammation in RA patients.
Background
Routinely collected data - such as databases of health
care insurance claims or the General Practice Research
database (GPRD) - have become a very important
source of information for studying secondary effects of
drugs [1-3]. They are useful as they usually provide
information on the health care history of many patients
for relatively long periods of time. Also, since the data
have already been collected, they allow investigation of
the secondary effects of drugs relatively quickly and
cheaply in comparison to randomised trials or prospec-
tive studies.
However, such routinely collected data have been rela-
tively rarely used in studies examining secondary effects
of drugs on progression/exacerbation of chronic diseases
[e.g. [4-8]]. As such databases are not compiled with
epidemiological research in mind, they usually provide
no information on clinical endpoints which do not
result in a new diagnosis or hospitalisation. Hence,
information on chronic conditions where the outcome
of interest is not a new recorded diagnosis or hospitali-
sation is often poor. Nevertheless, in certain situations,
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the prescription of a drug used to treat the symptoms of
a chronic disease may be regarded as a surrogate or
“substitute” for the outcome of interest [8,9]. For exam-
ple, anti-inflammatory drugs for flare-ups in autoim-
mune disease or anti-depressant drugs for depression.
Using prescriptions as a surrogate or “substitute” for
unmeasured endpoints raises a number of design and
analysis issues, which to our knowledge have not been
fully explored. First, we need a clinically and contex-
tually appropriate definition of how prescription of the
surrogate marker drug represents the unmeasured end-
point. Then, having chosen a surrogate prescription, we
have a modelling choice: time to surrogate initiation/
cessation or quantitative surrogate use.
If we choose the former, and take prescription as a
binary outcome, this can be analysed either by logistic
regression or by Cox regression using the time to the
event as outcome. It could also be analysed as a recur-
rent event for multiple prescriptions, though this
assumes that a second or subsequent prescription has
the same meaning as the first, which may be doubtful.
Furthermore, the event may be one of two types: for
those who are on the surrogate drug at the start of fol-
low-up, the event of interest would be stopping the sur-
rogate drug, while for those not on it at the start, the
event of interest is the first prescription of it.
If we take the latter, we need to summarise the
amount of the surrogate drug used in a specific period.
This could be cumulative dose or number and duration
of prescriptions where dosage information is limited or
varies very little. In both approaches the drug used as
surrogate outcome might be contraindicated in some
patients, and the information in the record may be
insufficient to determine whether it should be contra-
indicated. This complicates statistical modelling, which
should reflect the mix of contra and non-contra indi-
cated patients in the database.
Taking as a motivating example investigating the possi-
ble ameliorative effect of statin use on Rheumatoid
Arthritis flare-up, the aim of this paper is to describe and
critically compare the analysis options. This leads to gen-
eral recommendations concerning approaches to study-
ing secondary drug effects using routinely collected data
in chronic diseases. We have previously reported the
main results from our data [8], but here we focus on the
choice of the design and analysis of this type of study.
In Section 2 we give more detail on the research ques-
tion, and describe the routinely collected data we
analysed to investigate it. Section 2.1 describes a time-
to-initiation and time-to-cessation of surrogate drug
analysis and Section 2.2 an analysis based on the quan-
tity of the surrogate drug use. The results are presented
in Section 3. In Section 4 we critically evaluate the
various approaches, and also consider further under
which conditions a drug prescription can be regarded as
an appropriate surrogate or “substitute” for an endpoint
for the prognosis of a chronic disease. Finally, we out-
line the implications for similar future studies.
Methods
For our motivating example we investigate the suggestion
that statins may have anti-inflammatory effects [10-14]
and, in particular, that they may prevent or delay an
inflammatory flare-up in patients with Rheumatoid
Arthritis (RA). As RA is a long-term chronic disease with
a complex and only partially understood aetiology, char-
acterised by recurrent flare-ups, a large routinely col-
lected database is a natural source of information.
Data source
We used data from the LifeLink insurance claim data-
base which is available for research use [15]. This data-
base, whose former name was PharMetrics Patient
Centric Database, is collected, standardised and main-
tained by IMS Health [16]). This US medical and phar-
macy claims database recorded insurance claims on
1.8 million employees, their dependents and retirees
within an employer health care insurance scheme. The
database reports basic information on eligibility for care,
demographic characteristics, and both in- and out-
patient medical and pharmacy claims. The study was
approved by the Ethical Committee of the London
School of Hygiene and Tropical Medicine. Within the
database we identified a study population of 37477
patients with at least one medical claim for RA. The
first RA claim is regarded as a proxy for RA diagnosis.
A new diagnosis is not recorded unless there is a
claim, and while the recording of a claim within the
database is not necessarily the first date of a diagnosis it
is the best that can be done. We have noted [8] that
claims that occur early in the longitudinal record of a
patient are likely to be prevalent cases (and made allow-
ance for likely prevalent cases).
Choice of a surrogate marker of inflammatory status
In order to explore the anti-inflammatory effects of sta-
tins on RA patients a measure of inflammatory status is
needed. As direct information on inflammatory status is
not available in Lifelink, we treated the prescription of
oral steroids (OS) (prednisone and its derivates) as a
surrogate marker or ‘substitute’ for inflammatory status.
Initiation of OS therapy is a plausible marker for the
start of an inflammatory bout since such OS therapy
was commonly prescribed to keep inflammation under
control during the period when these data were col-
lected. Furthermore, because of the side effects of long-
term use of OS, such treatment is usually discontinued
as soon as the inflammation is under control. Having
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made this choice, as discussed in the introduction there
are two approaches to the analysis: model time to initia-
tion/cessation of OS therapy or model the quantity of
use of OS therapy. We now describe these in more
detail.
Cohort study for time to change in inflammation
We used an unmatched cohort study where initiation
and cessation of OS therapy were regarded as markers
for an increase and decrease in the underlying/unmea-
sured RA inflammatory process. We described this
study design in detail previously [8]. Briefly, the eligible
patients were split into two mutually exclusive sub-
cohorts based on whether they were not, or were, using
OS in a time window of RA index date +/-30 days
(Figures 1, 2). The rationale for this time window was
that recorded dates of prescriptions and diagnosis may
not be exact. Sub-cohort I included the patients not on
OS therapy at RA index date. The outcome event was
time to initiation of OS therapy defined as the first pre-
scription of OS (Figure 1). Sub-cohort II included the
patients who were on OS therapy at RA index date. The
outcome event for this was time to cessation of OS
therapy, defined as the date of the end of the first OS
prescription which was not followed by a subsequent
prescription within 45 days (Figure 2). To account for
the progressive nature of the disease, the time origin
was defined as RA index date in both sub-cohorts. As
patients who start statin therapy might stop it and
restart it later, we defined statin exposure as a time-
varying covariate. The research hypothesis was that if
statins have anti-inflammatory effects, then patients who
use statins should both have a reduced risk of initiating
OS therapy and an increased risk of cessation of OS
therapy compared to patients who do not take statins.
Separate Cox proportional hazards models were used
to evaluate the association between time-varying expo-
sure to statins and i) initiation of OS therapy in the non
users of OS at RA index date (sub-cohort I) and ii) ces-
sation of OS therapy in the users of OS at RA index
date (sub-cohort II). The models were adjusted for gen-
der, an indicator for RA incident cases (as time between
enrolment and first RA diagnosis > 6 months), medical
coverage (full versus partial) and health plan (indemnity
versus preferred provider organisation [PPO] scheme)
–since it is possible that type of insurance could affect
likelihood of prescriptions both for statins and OS) –
and, to account for the secular trend in use of statins
and changes in RA management over the period of the
study, calendar year of RA index date (1992 to 2002).
Models were adjusted by co-medications (non steroidal
anti-inflammatory drugs [NSAID], disease modifying
anti-rheumatic drugs [DMARD], ACE inhibitors, thia-
zide, loop diuretics, warfarin, beta blockers, angiotensin
II blockers, oral anti-diabetics and insulin) and co-
morbidities (diabetes mellitus, autoimmune disease
other than RA, osteoarthritis, asthma, chronic obstruc-
tive pulmonary disease [COPD], peptic ulcer, cardiovas-
cular disease) and oral steroids prescribed before RA
index date. More parsimonious models were selected by
retaining covariates with p-value < 0.1 in the full model
adjusted for all the covariates. The models were strati-
fied by age at RA index date (20-50, 51-70, and 70-88)
as this was found necessary for the assumption of
proportional hazards [17].
Matched cohort with amount of oral steroid prescribed as
outcome
We used a matched cohort study where new users of
statins (exposed group) were matched on the date of the
initiation of statin therapy 1 to 1 to patients without any
record of statin use in the previous year (unexposed
group) by sex and exact age. The statin index date was
defined as the calendar date of first statin prescription
for an exposed patient and the same date for the
matched unexposed patient.
Patients were included if they had at least one medical
claim for RA before statin index date, were aged more
than 20 years at first RA diagnosis (to exclude patients
with juvenile arthritis), and had at least 365 days of
membership of the database before the statin index date
(to ensure that a patient is truly a new user of statins
and to leave enough time to detect pre-exposure co-
morbidities and co-medications).
As Figure 3 shows, we defined the observation period
as the 365 days following the ‘run-in’ period of 90 days–
after which a patient can be considered fully exposed to
a statin [18].
Then, we analysed the data from this matched cohort
taking two different definitions of the outcome.
First, the outcome was defined as a binary variable
indicating whether the patient had used OS therapy dur-
ing the observation period (yes = 1, no = 0). The
research hypothesis was that if statins have an anti-
inflammatory effect, then patients who started statins
are less likely to use OS therapy during the observation
Event 'starting of OS therapy'
Exit from LifeLink 
databaseRA index date
Censoring 
Time since RA index date
Exit from LifeLink 
databaseRA index date
Figure 1 Definition of outcome event and censoring in the
sub-cohort I (non-users of OS at RA index date).
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period than the patients who did not have a statin. To
account for the matched nature the study design and
increase precision of the estimates we used conditional
logistic regression [19,20].
Second, the outcome was defined as the proportion of
days under OS therapy (as indicated in the pharmacy
records) in the observation period. The research hypoth-
esis was that if statins have an anti-inflammatory effect,
statin users will have on average fewer days of OS ther-
apy than non-users. Patients in the unexposed group
were censored if they initiated statins during the observa-
tion period. As a quick tool to compare the proportion of
Event 'cessation of OS therapy'
Duration OS1 + 45 days Duration OS2 + 45 days
Exit from LifeLink 
database
RA index date
Censoring 
Duration OS1 + 45 days Duration OS2 + 45 days
Time from RA index date
Exit from LifeLink 
databaseRA index date
Figure 2 Definition of outcome event and censoring in the sub-cohort II (users of OS at RA index date).
Figure 3 Structure of study cohort matched by sex and age.
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days under OS therapy in the observation period in the
two exposure groups, we used a paired Wilcoxon test. As
this test does not allow for adjustment of covariates, we
then used regression modelling for count data. As we
expected that a number of patients would have received
no OS therapy during their follow up, possibly due to
contra-indication, the zero inflated negative binomial
model was used to account for the outcome variable hav-
ing an excess of zeros [21]. This model assumes that the
data come from a mixture of two processes. In our set-
ting, the first is whether or not a patient receives OS
therapy. The second, if they received OS, how many days
they are prescribed (0,1,2), etc.
The model was adjusted for prescription of medica-
tions before the index date (disease modifying anti-rheu-
matic drugs [DMARDs], non steroidal anti-inflammatory
drugs [NSAIDs], digoxin, potassium sparing diuretic,
loop diuretic, thiazides, heparin, beta blockers, angioten-
sin II inhibitors, ACE inhibitors, clopidogrel bisulfate,
warfarin, anti-diabetics, insulin and oral steroids) and
morbidities before the index date (cardiovascular dis-
ease, diabetes mellitus, chronic obstructive pulmonary
disease [COPD], asthma, peptic ulcer disease and
osteoarthritis). In order to select a more parsimonious
model, for the binary part of the model we selected the
covariates which resulted in a p-value less than 0.1 from
a multivariable logistic regression. For the negative bino-
mial component, we used the covariates which resulted
in a p-value less than 0.1 from a multivariable negative
binomial model. We included an offset [i.e., loge(length
of patient follow-up)] to allow for the length of follow-
up time spent on OS therapy.
Finally, a quick way of assessing whether matching has
achieved balance and overlap is to plot histograms of
the propensity scores, ie the probability a patient
receives a statin given everything was observed before
the treatment, across exposed and the unexposed groups
[22]. For each patient, the propensity score was esti-
mated by fitting a multivariable logistic regression of
statin exposure (yes = 1, no = 0) on all baseline covari-
ates together with the first terms interactions and age to
the square. Overlap in the distribution of the propensity
score does not ensure that all predictors included in the
model are similarly matched, but they provide some
indication that their distributions have close balance
across the two groups
Results
Table 1 reports the estimated association between statin
use and OS prescription from each of the analyses
described above after adjustment for potential confoun-
ders. More detailed results are described below and in
Tables 2 and 3 and Tables 1 and 2 in Lodi et al [8].
Cohort study based on time to change in inflammation
After splitting patients according to their use of OS at
RA index date we found 31451 non users of OS at RA
index date and 6026 users of OS at RA index date.
Amongst the 31451 non users of OS at RA index date,
during a follow-up of 99749 person years, 11402 (36%)
began OS therapy during their follow up, and the med-
ian time to initiation of OS was 6.8 years. Amongst the
users of OS at RA index date 5490 (91%) ceased OS
therapy during their follow up of 4410.3 person-years.
The median time to OS cessation was 0.37 years.
In the sub-cohort of non users of OS at RA index
date, a hazard ratio <1 indicates a protective effect of
statin use on initiating OS therapy consistent with a
possible anti-inflammatory effect. As shown in Table 1,
the adjusted hazard ratio for statins of initiating OS
therapy was 0.956 (95% CI 0.901,1.015), hence statin use
only slightly and statistically non-significantly reduced
the likelihood of start of OS therapy. Baseline records
for diseases treated with OS like autoimmune disease,
asthma and COPD were associated with an increased
likelihood of initiating OS therapy [8]. On the other
hand, cardiovascular diseases such as cerebral haemor-
rhage and stroke, diabetes and hypertension were asso-
ciated with a decreased likelihood of initiating OS
therapy.
In the sub-cohort of users of OS at RA index date the
outcome was cessation of OS therapy. Hence, a protec-
tive effect of a covariate is indicated by a hazard ratio
>1 consistent with an anti-inflammatory effect. The
adjusted exposure hazard ratio of cessation of OS ther-
apy for statin use was 0.954 (95% CI 0.866, 1.051), indi-
cating that statin use had only a small and statistically
non-significant ‘prolonging’ effect on OS use. Cardiovas-
cular diseases such as angina, hypertension, and to a les-
ser extent, myocardial infarction were significant
predictors of cessation of OS therapy [8].
Matched cohort study with amount of OS prescription
outcome
The matching algorithm found 3144 patients newly
exposed to statins after RA diagnosis and 3144 unex-
posed patients matched in terms of age and sex. The
contribution to follow up was 3142 person-years and
3057 person-years in the exposed and unexposed group,
respectively. 372 patients entered the cohort in the
unexposed group but became statin users in the obser-
vation period. The distribution of the propensity score,
ie the probability of starting a statin given the observed
covariates, is shown in Figure 4. There was a slight ten-
dency for the exposed patients to have higher propensity
score values. Nevertheless, the distributions show an
overall overlap. 80% of patients (5034 out of 6288) had
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no OS prescription in the observation period (Figure
5a). Figure 5b shows that among patients with non zero
outcome, there is, not surprisingly, digit preference for 7
and multiples of 10 and.
When we used a binary outcome OS prescription was
slightly but not significantly less common among those
who were exposed to a statin (600/3144 patients) com-
pared with those who were not exposed (654/3144
patients) - matched-pair crude odds ratio f 0.901 (95%
CI 0.795,1.019, p = 0.093). When we used a multivari-
able conditional logistic regression to account for poten-
tial confounders (first row, Table 1), we found an
adjusted matched-pair odds ratio 1.064 (0.879,1.288, p =
0.523).
We then analysed the data using the quantitative out-
come duration of OS therapy in the observation period.
Due to the large proportion of patients with 0 duration
outcome, median [interquartile range] duration was 0 0
0 in both exposed and unexposed group. The results
from the unadjusted negative binomial model (rate ratio
0.792, 95% CI 0.608,1.030, p = 0.082) and the Wilcoxon
matched-pairs signed-ranks test for of the difference in
distribution of the paired differences in duration on OS
Table 1 Summary of methods and results after adjustment for potential confounders
Study design Outcome Statistical methods Estimate of effect of statin
exposure *
P
Matched cohort Use of OS in the observation period Conditional logistic regression Odds ratio 1.064 (0.879,1.288) 0.523
Number of days on OS therapy in the
observation period
Zero inflated negative binomial
model
a) Odds ratio 1.025 (0.900,1.169) 0.704
b) Rate ratio 0.879 (0.758,1.021) 0.091
Unmatched
cohort ^
Time to initiation of OS therapy Cox model Hazard ratio 0.956 (0.901,1.015) 0.14
Time to cessation of OS therapy Cox model Hazard ratio 0.954 (0.866,1.051) 0.34
*Baseline reference: not exposed to statins.
^Results presented in reference [8].
Table 2 Matched cohort study
Odds ratio 95% confidence
interval
P
Statin exposure 1.064 0.879 1.288 0.523
Fibrate 1.167 0.905 1.504 0.233
Ace inhibitors 0.961 0.911 1.014 0.144
Digoxin 1.005 0.919 1.098 0.92
Warfarin 1.078 0.951 1.223 0.242
Loop diuretic 1.01 0.888 1.149 0.879
NSAID 1.014 0.976 1.054 0.472
OS 2.158 1.881 2.477 <0.001
Thiazide 0.98 0.909 1.058 0.612
DMARD 1.083 1.042 1.126 <0.001
Potassium sparing 1.029 0.905 1.169 0.665
Beta blockers 1.029 0.958 1.105 0.433
Angiotensine 1.071 0.948 1.211 0.268
Clopidogrel 1.091 0.888 1.341 0.408
Hyperlipidemia 0.805 0.607 1.067 0.131
Transient Ischaemic attack 1.153 0.706 1.882 0.569
Osteoarthritis 1.2 0.924 1.558 0.172
Angina 0.918 0.707 1.192 0.522
Asthma COPD 1.638 1.263 2.124 <0.001
Myocardial infarction 1.299 0.853 1.98 0.223
Diabetes 0.455 0.271 0.764 0.003
Hypertersion 1.147 0.485 2.714 0.754
Stroke 0.744 0.502 1.101 0.139
Peptic Ulcer 0.81 0.408 1.608 0.546
Cerebral Heamorragea 1.098 0.509 2.367 0.811
Heart failure 0.569 0.172 1.889 0.357
Results from the conditional logistic regression adjusted for morbities and
medications before the index date.
Table 3 Matched cohort study
Rate ratio 95% Confidence interval P
Statin 0.879 0.758 1.021 0.091
Asthma COPD 0.815 0.676 0.983 0.032
Osteoarthritis 0.854 0.715 1.019 0.081
Hyperlipidemia 0.808 0.665 0.981 0.031
Hypertension 0.855 0.72 1.017 0.076
Peptic ulcer disease 0.763 0.538 1.082 0.13
OS 1.356 1.148 1.602 <0.001
DMARDs 1.545 1.282 1.862 <0.001
NSAID 0.757 0.637 0.899 0.002
Odds Ratio 95% confidence interval P
Statin 1.025 0.900 1.169 0.704
Diabetes mellitus 1.369 1.107 1.690 0.004
Asthma COPD 0.829 0.703 0.977 0.026
Hyperlipidemia 1.428 1.210 1.685 <0.001
Hypertension 1.171 1.010 1.359 0.037
OS 0.386 0.332 0.450 <0.001
DMARD 0.433 0.363 0.517 <0.001
Loop diuretics 1.242 0.938 1.644 0.13
Anti-diabetics 1.895 1.334 2.691 <0.001
Results from the zero inflated negative binomial model. Parsimonious model
including all covariates (morbidities and medications at the index date)
with p-value less than 0.1. The model has two components. Bottom: logistic
model component predicting the probability of NOT having OS. Top: negative
binomial model component predicting the rate of OS duration in an
observation period of length 365 days for those patients who have OS.
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therapy in the observation period (p = 0.036) both indi-
cated some evidence of differences. Results from the
adjusted zero inflated negative binomial model are pre-
sented in Table 1. The statin exposure odds ratio of
1.025 (95% CI 0.900,1.168) estimated from the logistic
component predicting the probability of having OS (a)
suggests that exposure to statins does not affect whether
or not a patient is likely to be prescribed with OS ther-
apy in the observation period. The statin exposure rate
ratio of 0.88 (95% CI 0.79,1.06) estimated from the
negative binomial component predicting the rate of OS
duration in the observation period for those patients
who have OS estimates (b) shows that among patients
who received OS, the data are consistent with the
hypothesis that statin exposure does not affect the rate
of OS duration, though there is a hint that they could
be protective. The full model is presented in Table 3.
Here, history of diabetes, hyperlipidemia, hypertension
and oral anti-diabetics have an increased odds of not
being prescribed OS in the observation period, while
patients with history of OS, asthma or COPD, DMARD
are more likely to have OS therapy in the observation
period.
Discussion
We have described and illustrated two approaches to
cohort study design that can be used to explore the pos-
sible secondary effects of a drug on a chronic disease
using routinely collected databases. This work was moti-
vated by the study of the anti-inflammatory effects of
statins in RA patients using the LifeLink database: we
explored possible anti-inflammatory effect of statins in
Rheumatoid Arthritis where oral steroid (OS) prescrip-
tion was chosen as a surrogate or “substitute” outcome
for flare up. None of the proposed study designs pro-
vided convincing evidence of a protective effect for
0
5
10
15
20
Pe
rc
en
ta
ge
0 .25 .5 .75 1
Propensity Score
Exposed to statins
0
5
10
15
20
Pe
rc
e
n
ta
ge
0 .25 .5 .75 1
Propensity Score
Unexposed to statins
Figure 4 Matched cohort study. Distribution of the propensity score by exposure group.
0
10
00
20
00
30
00
40
00
50
00
Fr
eq
u
e
n
cy
0 30 60 90 120 150 180 210 240 270 300 330 360
Number of days under OS treatment
0
50
10
0
15
0
Fr
eq
ue
nc
y
0 30 60 90 120 150 180 210 240 270 300 330 360
Number of days under OS treatment
Figure 5 Matched cohort study. Distribution of number of days on OS therapy in the observation period: left panel- all patients; right panel:
excluding patients who did not initiate OS therapy.
Lodi et al. BMC Medical Research Methodology 2011, 11:36
http://www.biomedcentral.com/1471-2288/11/36
Page 7 of 9
statins. A full discussion on the exposure definition and
limitations of using routinely collected LifeLink database
for studying the anti-inflammatory effects of statins is
reported elsewhere [8]. Here our focus is on the pros
and cons of the two approaches, which are well illu-
strated by our study.
In the first approach, the design was based on time to
change OS therapy status, as a surrogate for the true
outcome of interest, change in inflammation. The work-
ing hypothesis was that if statins have anti-inflammatory
effects, then patients who use statins should both have a
reduced risk of initiating OS therapy and an increased
risk of cessation of OS therapy compared to similar
patients who do not take statins.
In the second approach, we matched new statin users
(when they initiated therapy) to patients who were not
on statin therapy 1 to 1 on age and sex. The working
hypothesis was that if statins have anti-inflammatory
effects, then statin users should require OS for a shorter
period compared to non users.
We now argue that the time-to-initiation/cessation
approach is superior to the matched cohort study
being both statistically more straightforward and epide-
miologically more convincing. Consider the following
points.
First, an awkward complicating issue when using the
second approach is that a non-trivial proportion of
patients will not be eligible for the surrogate medication
(in our case OS therapy) for a variety of reasons that are
often difficult to model. For example in our study 80%
of patients did not have OS therapy in the observation
period; this is an unidentified mix of those who are, and
are not, eligible. By contrast, the first approach of split-
ting the cohort into two sub-cohorts (those under, and
not under, OS therapy at RA index date) neatly side-
steps this first issue. A further advantage in the time-to-
initiation/cessation approach both groups are modelled
separately, allowing different-specific-adjustment for
confounding.
Second, the Cox proportional hazard model (with
appropriate use of stratification) provides a flexible fra-
mework for modelling the time-to-event (initiation or
cessation of OS therapy in our example). In our case,
this fitted the data satisfactorily. By contrast, with the
second approach we must model the typically awkward
data on surrogate (here OS) therapy use. Indeed, not
only are such data often awkward to model, they are
markedly affected by measurement error. In our study,
both the extent of impossible doses removed in the data
cleaning process, and the marked digit preference at 10
and 30 days, illustrate this.
Third, separately modelling the time to initiation/ces-
sation of surrogate therapy means that - if the results
are consistent - we can be more confident they are not
substantially confounded. This is because the approach
splits the patients into two sub-cohorts at index date, in
which different mechanisms are at work, and these are
independently followed-up and analysed. The analysis
can then readily account for the fact that some predic-
tors for initiation of surrogate therapy may differ from
those for cessation of surrogate therapy. Further unmea-
sured confounders will likely work differently in the two
cohorts. Thus, if – as in our case – the two sub-cohorts
give compatible conclusions (i.e. one hazard ratio>1 and
one hazard ratio<1), then we can be more confident the
results are not substantially confounded.
Fourth, by splitting the available patients into non
users/users of the surrogate therapy at index date the
first approach also provides some degree of robustness
with regard to contraindication of the surrogate therapy.
For example in our study, patients who have a very low
chance of being prescribed with OS because of contrain-
dications are more likely to be part of the subcohort I,
than in subcohort II. If a similar effect is found in both
sub-cohorts, we are more confident the conclusions are
robust.
Fifth, in our matched study only a minority of the
available patients (20%) had at least one OS prescription
in the observation period. Hence, the statistical power
was reduced. This is typical in our experience. While a
natural next step would be to increase the matching
ratio, by attempting to match 1:M, unfortunately the
gain in power/efficiency from each additional match
quickly declines [23,24]. Further increasing the number
of matches inevitably involves widening the matching
‘calipers’ so that the benefit of matching is reduced.
Sixth, and finally, in the time to event approach,
patients can naturally contribute repeated episodes to
the analysis (eg time to first initiation, then time from
initiation to cessation etc.). We investigated this
approach for these data, but it did not alter the substan-
tive conclusions.
In summary, methodological and epidemiological con-
siderations strongly favour the first approach.
Lastly, the use of surrogate end points has been criti-
cised and it has been suggested that surrogate outcomes
should not been used without validation studies proving
that the treatment effect of interest is the same in the
surrogate and in the endpoint of clinical importance
[25,26]. While validation studies are clearly desirable, we
argue such a dogmatic approach is not always appropri-
ate or helpful. In the case of our motivating example,
while a validation study showing that the effect of sta-
tins in RA patients is the same on the inflammatory sta-
tus and on the risk of initiation/cessation of OS therapy
has not been conducted, we think that OS prescription
can be regarded as an appropriate surrogate marker or
“substitute” for inflammatory status, because many if
Lodi et al. BMC Medical Research Methodology 2011, 11:36
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not most patients will start OS therapy quickly in
response to an RA flare-up and most will stop OS ther-
apy after a flare-up ends - not least because the side
effects of OS therapy. We believe that in similar settings
– such as prescription of antidepressants as a surrogate
marker for depression, prescription of anti-histamine for
allergies, anti-inflammatory drugs for autoimmune dis-
ease flare-ups – the use of prescriptions as surrogate
markers (or substitutes) for the otherwise unrecorded
status of chronic diseases is key to realising the full
potential of routinely collected databases.
Conclusions
We have compared, contrasted and illustrated two dif-
ferent approaches to the use of routinely collected data-
bases for assessing the secondary effect of exposure on
the prognosis of chronic disease. We used a surrogate
therapy for the status of the chronic disease. The first
approach was based on time to initiation/cessation of
the surrogate therapy. The second approach used a
matched cohort study to model the use of surrogate
therapy. We have elucidated and illustrated six reasons
why the first approach is preferred from both a statisti-
cal and epidemiological perspective. We therefore advo-
cate the time-to-event approach as the method of
choice for such studies.
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